The BCR regulates the activity of GSK-3 in CLL cells through an AKT-independent/PKC-dependent pathway. (A) Schematic representation of BCR signaling molecules involved in regulating GSK-3 activity and Mcl-1 expression. (B) Dose titration effects of sotrastaurin (Sotr), GS-9973 (GS), ibrutinib, and idelalisib, on GSK-3 and AKT phosphorylation were evaluated in anti-IgM–stimulated CLL cells. One representative experiment out of 3 performed is shown.